An observational study in Glioblastoma, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by University Hospital, Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Glioblastoma with a site in France — 35 open to participants now, 51 under way, 9 of them phase 3. Glioblastoma · France.
Among the 150 studies in Glioblastoma with a site in France, this one is the 13th largest by planned enrollment of the 18 observational ones that give a count, is one of 8 that started in 2025, is one of 18 observational ones, reaches primary completion later than 48 of the 50 other live ones, and was the 125th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →35 of the 150 studies in Glioblastoma with a site in France are open now. Recruiting first, the newest first:
Beta Emitting Accurate Monitored Systems · Sites in France
Ages 18+
Centre Paul Strauss · Sites in France
Ages 18+
Centre Paul Strauss · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 58 · Phase 3 27 · Phase 4 1
First in 1999; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 60 across 208 observational studies indexed under Glioblastoma.
Median enrollment 80 across the 131 interventional studies, 114 across the 18 observational. Of the 92 that completed or were terminated, 23 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 150 have an industry lead sponsor. The 10 most frequent:
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
University Hospital, Bordeaux has 4 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
14 of the studies in Glioblastoma with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03663725Phase 3Centre Oscar LambretTreatment Intensification With Temozolomide in Adults With a Glioblastoma | 2027-06 |
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
| NCT04881032Centre Jean PerrinAGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT06001281Assistance Publique Hopitaux De MarseillePredictive Value of Soluble CD146 in Glioblastoma Patients | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 150 studies in Glioblastoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Glioblastoma is the most common and aggressive primary brain tumor in adults, whose relapse is almost systematic despite surgery, radiation therapy and temozolomide (STUPP protocol). Several clinical trials evaluating targeted therapy and immune checkpoint inhibitors have led to disappointed results. There is an unmet need to better understand the molecular and immune mechanisms underlying the invasion and progression of these tumors, in order to identify new therapeutic targets. The Bordeaux University Hospital is a leading French treatment center for glioblastoma, providing a large number of biological samples that can be analyzed at the molecular, immune and metabolic levels by specialized local teams.
Tumor tissue will be collected during patient surgery from primitive or recurrent glioblastoma, as well as blood samples, to perform transcriptomic and metabolomic analysis, including spatial transcriptomic and metabolomic, ex vivo generation of γδT lymphocytes and patient-derived xenografts.
A secondary objective is to develop, in preclinical models, innovative drugs with radiosensitizing effect and a γδT cell immunotherapy active against glioblastoma.
Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glioblastoma patient with indication for neurosurgery
Other: samples
A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.
Molecular mechanism
Description of the molecular mechanism involved in the progression and recurrence of glioblastoma
Time frame: at inclusion (T0)
Metabolic mechanism
Description of the metabolic mechanism involved in the progression and recurrence of glioblastoma.
Time frame: at inclusion (T0)
Immune mechanism
Description of the immune mechanism involved in the progression and recurrence of glioblastoma
Time frame: at inclusion (T0)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2031, 72 months after the start.
Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 72 months is above that.
Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →